

Appendix 4G

Key to Disclosures

Corporate Governance Council Principles and Recommendations

Name of entity

Anatara Lifesciences Ltd

ABN/ARBN

41 145 239 872

Financial year ended:

30 June 2024

Our corporate governance statement¹ for the period above can be found at:²

- ☐ These pages of our annual report:
- ☒ This URL on our website: <https://anataralifesciences.com/investors/corporate-governance>

The Corporate Governance Statement is accurate and up to date as at 2 October 2024 and has been approved by the Anatara Board.

The annexure includes a key to where our corporate governance disclosures can be located.³

Date: 2 October 2024

Name of authorised officer
authorising lodgement: Stephen Denaro

¹ "Corporate governance statement" is defined in Listing Rule 19.12 to mean the statement referred to in Listing Rule 4.10.3 which discloses the extent to which an entity has followed the recommendations set by the ASX Corporate Governance Council during a particular reporting period.

Listing Rule 4.10.3 requires an entity that is included in the official list as an ASX Listing to include in its annual report either a corporate governance statement that meets the requirements of that rule or the URL of the page on its website where such a statement is located. The corporate governance statement must disclose the extent to which the entity has followed the recommendations set by the ASX Corporate Governance Council during the reporting period. If the entity has not followed a recommendation for any part of the reporting period, its corporate governance statement must separately identify that recommendation and the period during which it was not followed and state its reasons for not following the recommendation and what (if any) alternative governance practices it adopted in lieu of the recommendation during that period.

Under Listing Rule 4.7.4, if an entity chooses to include its corporate governance statement on its website rather than in its annual report, it must lodge a copy of the corporate governance statement with ASX at the same time as it lodges its annual report with ASX. The corporate governance statement must be current as at the effective date specified in that statement for the purposes of Listing Rule 4.10.3.

Under Listing Rule 4.7.3, an entity must also lodge with ASX a completed Appendix 4G at the same time as it lodges its annual report with ASX. The Appendix 4G serves a dual purpose. It acts as a key designed to assist readers to locate the governance disclosures made by a listed entity under Listing Rule 4.10.3 and under the ASX Corporate Governance Council's recommendations. It also acts as a verification tool for listed entities to confirm that they have met the disclosure requirements of Listing Rule 4.10.3.

The Appendix 4G is not a substitute for, and is not to be confused with, the entity's corporate governance statement. They serve different purposes and an entity must produce each of them separately.

² Tick whichever option is correct and then complete the page number(s) of the annual report, or the URL of the web page, where your corporate governance statement can be found. You can, if you wish, delete the option which is not applicable.

³ Throughout this form, where you are given two or more options to select, you can, if you wish, delete any option which is not applicable and just retain the option that is applicable. If you select an option that includes "OR" at the end of the selection and you delete the other options, you can also, if you wish, delete the "OR" at the end of the selection.

See notes 4 and 5 below for further instructions on how to complete this form.

ANNEXURE – KEY TO CORPORATE GOVERNANCE DISCLOSURES

Corporate Governance Council recommendation		Where a box below is ticked, ⁴ we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: ⁵
PRINCIPLE 1 – LAY SOLID FOUNDATIONS FOR MANAGEMENT AND OVERSIGHT			
1.1	A listed entity should have and disclose a board charter setting out: (a) the respective roles and responsibilities of its board and management; and (b) those matters expressly reserved to the board and those delegated to management.	☒ and we have disclosed a copy of our board charter at: https://anataralifesciences.com/investors/corporate-governance/	☐ set out in our Corporate Governance Statement OR ☐ we are an externally managed entity and this recommendation is therefore not applicable
1.2	A listed entity should: (a) undertake appropriate checks before appointing a director or senior executive or putting someone forward for election as a director; and (b) provide security holders with all material information in its possession relevant to a decision on whether or not to elect or re-elect a director.	☒	☐ set out in our Corporate Governance Statement OR ☐ we are an externally managed entity and this recommendation is therefore not applicable
1.3	A listed entity should have a written agreement with each director and senior executive setting out the terms of their appointment.	☒	☐ set out in our Corporate Governance Statement OR ☐ we are an externally managed entity and this recommendation is therefore not applicable
1.4	The company secretary of a listed entity should be accountable directly to the board, through the chair, on all matters to do with the proper functioning of the board.	☒	☐ set out in our Corporate Governance Statement OR ☐ we are an externally managed entity and this recommendation is therefore not applicable

⁴ Tick the box in this column only if you have followed the relevant recommendation **in full** for the **whole** of the period above. Where the recommendation has a disclosure obligation attached, you must insert the location where that disclosure has been made, where indicated by the line with “*insert location*” underneath. If the disclosure in question has been made in your corporate governance statement, you need only insert “our corporate governance statement”. If the disclosure has been made in your annual report, you should insert the page number(s) of your annual report (eg “pages 10-12 of our annual report”). If the disclosure has been made on your website, you should insert the URL of the web page where the disclosure has been made or can be accessed (eg “www.entityname.com.au/corporate-governance/charters/”).

⁵ If you have followed all of the Council’s recommendations **in full** for the **whole** of the period above, you can, if you wish, delete this column from the form and re-format it.

Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation	Where a box below is ticked, ⁴ we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: ⁵
1.5 A listed entity should: (a) have and disclose a diversity policy; (b) through its board or a committee of the board set measurable objectives for achieving gender diversity in the composition of its board, senior executives and workforce generally; and (c) disclose in relation to each reporting period: (1) the measurable objectives set for that period to achieve gender diversity; (2) the entity's progress towards achieving those objectives; and (3) either: (A) the respective proportions of men and women on the board, in senior executive positions and across the whole workforce (including how the entity has defined "senior executive" for these purposes); or (B) if the entity is a "relevant employer" under the Workplace Gender Equality Act, the entity's most recent "Gender Equality Indicators", as defined in and published under that Act. If the entity was in the S&P / ASX 300 Index at the commencement of the reporting period, the measurable objective for achieving gender diversity in the composition of its board should be to have not less than 30% of its directors of each gender within a specified period.	☒ and we have disclosed a copy of our diversity policy at: https://anataralifesciences.com/investors/corporate-governance/ and we have disclosed the information referred to in paragraph (c) at: https://anataralifesciences.com/investors/corporate-governance/ and if we were included in the S&P / ASX 300 Index at the commencement of the reporting period our measurable objective for achieving gender diversity in the composition of its board of not less than 30% of its directors of each gender within a specified period.	☐ set out in our Corporate Governance Statement OR ☐ we are an externally managed entity and this recommendation is therefore not applicable
1.6 A listed entity should: (a) have and disclose a process for periodically evaluating the performance of the board, its committees and individual directors; and (b) disclose for each reporting period whether a performance evaluation has been undertaken in accordance with that process during or in respect of that period.	☒ and we have disclosed the evaluation process referred to in paragraph (a) at: https://anataralifesciences.com/investors/corporate-governance/ and whether a performance evaluation was undertaken for the reporting period in accordance with that process at: https://anataralifesciences.com/investors/corporate-governance/	☐ set out in our Corporate Governance Statement OR ☐ we are an externally managed entity and this recommendation is therefore not applicable

Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation		Where a box below is ticked, ⁴ we have followed the recommendation <u>in full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: ⁵
1.7	A listed entity should: (a) have and disclose a process for evaluating the performance of its senior executives at least once every reporting period; and (b) disclose for each reporting period whether a performance evaluation has been undertaken in accordance with that process during or in respect of that period.	☒ and we have disclosed the evaluation process referred to in paragraph (a) at: https://anataralifesciences.com/investors/corporate-governance/ and whether a performance evaluation was undertaken for the reporting period in accordance with that process at: https://anataralifesciences.com/investors/corporate-governance/ https://anataralifesciences.com/investors/annual-reports/	☐ set out in our Corporate Governance Statement OR ☐ we are an externally managed entity and this recommendation is therefore not applicable

Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation		Where a box below is ticked, ⁴ we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: ⁵
PRINCIPLE 2 - STRUCTURE THE BOARD TO BE EFFECTIVE AND ADD VALUE			
2.1	The board of a listed entity should: (a) have a nomination committee which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have a nomination committee, disclose that fact and the processes it employs to address board succession issues and to ensure that the board has the appropriate balance of skills, knowledge, experience, independence and diversity to enable it to discharge its duties and responsibilities effectively.	☒ <i>[If the entity complies with paragraph (a):]</i> and we have disclosed a copy of the charter of the committee at: https://anataralifesciences.com/investors/corporate-governance/ and the information referred to in paragraphs (4) and (5) at: https://anataralifesciences.com/investors/corporate-governance/ https://anataralifesciences.com/investors/annual-reports/ <i>[If the entity complies with paragraph (b):]</i> and we have disclosed the fact that we have a combined Remuneration & Nominations Committee, currently do not meet (a)(1) & (2) and the processes we employ to address board succession issues and to ensure that the board has the appropriate balance of skills, knowledge, experience, independence and diversity to enable it to discharge its duties and responsibilities effectively at: https://anataralifesciences.com/investors/corporate-governance/	☐ set out in our Corporate Governance Statement OR ☐ we are an externally managed entity and this recommendation is therefore not applicable
2.2	A listed entity should have and disclose a board skills matrix setting out the mix of skills that the board currently has or is looking to achieve in its membership.	☒ and we have disclosed our board skills matrix at: https://anataralifesciences.com/investors/corporate-governance/	☐ set out in our Corporate Governance Statement OR ☐ we are an externally managed entity and this recommendation is therefore not applicable

Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation		Where a box below is ticked, ⁴ we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: ⁵
2.3	A listed entity should disclose: (a) the names of the directors considered by the board to be independent directors; (b) if a director has an interest, position, affiliation or relationship of the type described in Box 2.3 but the board is of the opinion that it does not compromise the independence of the director, the nature of the interest, position or relationship in question and an explanation of why the board is of that opinion; and (c) the length of service of each director.	☒ and we have disclosed the names of the directors considered by the board to be independent directors at: https://anataralifesciences.com/investors/corporate-governance/ https://anataralifesciences.com/investors/annual-reports/ and, where applicable, the information referred to in paragraph (b) at: and the length of service of each director at: https://anataralifesciences.com/investors/corporate-governance/ https://anataralifesciences.com/investors/annual-reports/ Note the chair is an executive chair and that the company appointed a concurrent COO (Chief Operating Officer) as a new position with this structure likely to remain until a full-time CEO is engaged. On 2 October 2023 the COO was appointed an executive director on the retirement of a non-executive director at that time.	☐ set out in our Corporate Governance Statement
2.4	A majority of the board of a listed entity should be independent directors.	☒ Note two of a three director board are executive directors. This includes an executive chair and that the company appointed a concurrent COO (Chief Operating Officer) as a new position with this structure to remain until a full-time CEO is engaged. The second executive director (COO) was appointed on 2 October 2023 due to the then retirement of a non-executive director. It is anticipated that the process to appoint a full-time CEO will occur in this financial year and the chair will transition to being a non-executive chair. It is intended for the majority of the board to be independent non-executive directors as soon as practicable.	☐ set out in our Corporate Governance Statement OR ☐ we are an externally managed entity and this recommendation is therefore not applicable
2.5	The chair of the board of a listed entity should be an independent director and, in particular, should not be the same person as the CEO of the entity.	☒ Note the chair is an executive chair and that the company appointed a concurrent COO (Chief Operating Officer) as a new position with this structure likely to remain until a full-time CEO is engaged. At that time the chair will transition to being a non-executive chair.	☐ set out in our Corporate Governance Statement OR ☐ we are an externally managed entity and this recommendation is therefore not applicable

Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation		Where a box below is ticked, ⁴ we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: ⁵
2.6	A listed entity should have a program for inducting new directors and for periodically reviewing whether there is a need for existing directors to undertake professional development to maintain the skills and knowledge needed to perform their role as directors effectively.	☒	☐ set out in our Corporate Governance Statement OR ☐ we are an externally managed entity and this recommendation is therefore not applicable
PRINCIPLE 3 – INSTIL A CULTURE OF ACTING LAWFULLY, ETHICALLY AND RESPONSIBLY			
3.1	A listed entity should articulate and disclose its values.	☒ and we have disclosed our values at: https://anataralifesciences.com/investors/corporate-governance/	☐ set out in our Corporate Governance Statement
3.2	A listed entity should: (a) have and disclose a code of conduct for its directors, senior executives and employees; and (b) ensure that the board or a committee of the board is informed of any material breaches of that code.	☒ and we have disclosed our code of conduct at: https://anataralifesciences.com/investors/corporate-governance/	☐ set out in our Corporate Governance Statement
3.3	A listed entity should: (a) have and disclose a whistleblower policy; and (b) ensure that the board or a committee of the board is informed of any material incidents reported under that policy.	☒ and we have disclosed our whistleblower policy at: https://anataralifesciences.com/investors/corporate-governance/	☐ set out in our Corporate Governance Statement
3.4	A listed entity should: (a) have and disclose an anti-bribery and corruption policy; and (b) ensure that the board or committee of the board is informed of any material breaches of that policy.	☒ and we have disclosed our anti-bribery and corruption policy at: https://anataralifesciences.com/investors/corporate-governance/	☐ set out in our Corporate Governance Statement

Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation		Where a box below is ticked, ⁴ we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: ⁵
PRINCIPLE 4 – SAFEGUARD THE INTEGRITY OF CORPORATE REPORTS			
4.1	The board of a listed entity should: (a) have an audit committee which: (1) has at least three members, all of whom are non-executive directors and a majority of whom are independent directors; and (2) is chaired by an independent director, who is not the chair of the board, and disclose: (3) the charter of the committee; (4) the relevant qualifications and experience of the members of the committee; and (5) in relation to each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have an audit committee, disclose that fact and the processes it employs that independently verify and safeguard the integrity of its corporate reporting, including the processes for the appointment and removal of the external auditor and the rotation of the audit engagement partner.	☒ <i>[If the entity complies with paragraph (a):]</i> and we have disclosed a copy of the charter of the committee at: https://anataralifesciences.com/investors/corporate-governance/ and the information referred to in paragraphs (4) and (5) at: https://anataralifesciences.com/investors/corporate-governance/ https://anataralifesciences.com/investors/annual-reports/ <i>[If the entity complies with paragraph (b):]</i> and we have disclosed the fact that we have an Audit and Risk Management Committee, that we do not currently meet (a)(1) and the processes we employ that independently verify and safeguard the integrity of our corporate reporting, including the processes for the appointment and removal of the external auditor and the rotation of the audit engagement partner. The Audit and Risk Management Committee is chaired by an independent non-executive director. Refer: https://anataralifesciences.com/investors/corporate-governance/	☐ set out in our Corporate Governance Statement
4.2	The board of a listed entity should, before it approves the entity's financial statements for a financial period, receive from its CEO and CFO a declaration that, in their opinion, the financial records of the entity have been properly maintained and that the financial statements comply with the appropriate accounting standards and give a true and fair view of the financial position and performance of the entity and that the opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.	☒	☐ set out in our Corporate Governance Statement
4.3	A listed entity should disclose its process to verify the integrity of any periodic corporate report it releases to the market that is not audited or reviewed by an external auditor.	☒	☐ set out in our Corporate Governance Statement

Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation		Where a box below is ticked, ⁴ we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: ⁵
PRINCIPLE 5 – MAKE TIMELY AND BALANCED DISCLOSURE			
5.1	A listed entity should have and disclose a written policy for complying with its continuous disclosure obligations under listing rule 3.1.	☒ and we have disclosed our continuous disclosure compliance policy at: https://anataralifesciences.com/investors/corporate-governance/	☐ set out in our Corporate Governance Statement
5.2	A listed entity should ensure that its board receives copies of all material market announcements promptly after they have been made.	☒	☐ set out in our Corporate Governance Statement
5.3	A listed entity that gives a new and substantive investor or analyst presentation should release a copy of the presentation materials on the ASX Market Announcements Platform ahead of the presentation.	☒	☐ set out in our Corporate Governance Statement
PRINCIPLE 6 – RESPECT THE RIGHTS OF SECURITY HOLDERS			
6.1	A listed entity should provide information about itself and its governance to investors via its website.	☒ and we have disclosed information about us and our governance on our website at: https://anataralifesciences.com/investors/corporate-governance/	☐ set out in our Corporate Governance Statement
6.2	A listed entity should have an investor relations program that facilitates effective two-way communication with investors.	☒	☐ set out in our Corporate Governance Statement
6.3	A listed entity should disclose how it facilitates and encourages participation at meetings of security holders.	☒ and we have disclosed how we facilitate and encourage participation at meetings of security holders at: https://anataralifesciences.com/investors/corporate-governance/	☐ set out in our Corporate Governance Statement
6.4	A listed entity should ensure that all substantive resolutions at a meeting of security holders are decided by a poll rather than by a show of hands.	☒	☐ set out in our Corporate Governance Statement

Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation		Where a box below is ticked, ⁴ we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: ⁵
6.5	A listed entity should give security holders the option to receive communications from, and send communications to, the entity and its security registry electronically.	☒	☐ set out in our Corporate Governance Statement
PRINCIPLE 7 – RECOGNISE AND MANAGE RISK			
7.1	The board of a listed entity should: (a) have a committee or committees to oversee risk, each of which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have a risk committee or committees that satisfy (a) above, disclose that fact and the processes it employs for overseeing the entity's risk management framework.	☒ <i>[If the entity complies with paragraph (a):]</i> and we have disclosed a copy of the charter of the committee at: https://anataralifesciences.com/investors/corporate-governance/ and the information referred to in paragraphs (4) and (5) at: https://anataralifesciences.com/investors/corporate-governance/ https://anataralifesciences.com/investors/annual-reports/ <i>[If the entity complies with paragraph (b):]</i> and we have disclosed the fact that we have an Audit and Risk Management Committee or committees that does not satisfy (a)(1) and the processes we employ for overseeing our risk management framework at: https://anataralifesciences.com/investors/corporate-governance/ With the retirement of an independent non-executive director on 2 October 2023, the Audit and Risk Management Committee currently has three members including two executive directors. The Audit and Risk Management Committee is chaired by an independent non-executive director.	☐ set out in our Corporate Governance Statement
7.2	The board or a committee of the board should: (a) review the entity's risk management framework at least annually to satisfy itself that it continues to be sound and that the entity is operating with due regard to the risk appetite set by the board; and (b) disclose, in relation to each reporting period, whether such a review has taken place.	☒ and we have disclosed whether a review of the entity's risk management framework was undertaken during the reporting period at: https://anataralifesciences.com/investors/corporate-governance/	☐ set out in our Corporate Governance Statement

Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation		Where a box below is ticked, ⁴ we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: ⁵
7.3	A listed entity should disclose: (a) if it has an internal audit function, how the function is structured and what role it performs; or (b) if it does not have an internal audit function, that fact and the processes it employs for evaluating and continually improving the effectiveness of its governance, risk management and internal control processes.	☒ <i>[If the entity complies with paragraph (a):]</i> and we have disclosed how our internal audit function is structured and what role it performs at: <i>[insert location]</i> <i>[If the entity complies with paragraph (b):]</i> Anatara has disclosed the fact that we do not have an internal audit function and the processes we employ for evaluating and continually improving the effectiveness of our risk management and internal control processes at below and via the Audit and Risk Management Committee: https://anataralifesciences.com/investors/corporate-governance/	☐ set out in our Corporate Governance Statement
7.4	A listed entity should disclose whether it has any material exposure to environmental or social risks and, if it does, how it manages or intends to manage those risks.	☒ and we have disclosed whether we have any material exposure to environmental and social risks at: https://anataralifesciences.com/investors/corporate-governance/ and, if we do, how we manage or intend to manage those risks at: https://anataralifesciences.com/investors/corporate-governance/	☐ set out in our Corporate Governance Statement

Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation		Where a box below is ticked, ⁴ we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: ⁵
PRINCIPLE 8 – REMUNERATE FAIRLY AND RESPONSIBLY			
8.1	The board of a listed entity should: (a) have a remuneration committee which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have a remuneration committee, disclose that fact and the processes it employs for setting the level and composition of remuneration for directors and senior executives and ensuring that such remuneration is appropriate and not excessive.	☒ <i>[If the entity complies with paragraph (a):]</i> and we have disclosed a copy of the charter of the committee at: https://anataralifesciences.com/investors/corporate-governance/ and the information referred to in paragraphs (4) and (5) at: https://anataralifesciences.com/investors/corporate-governance/ https://anataralifesciences.com/investors/annual-reports/ <i>[If the entity complies with paragraph (b):]</i> Anatara has disclosed the fact that we have a Remuneration and Nominations Committee and the processes we employ for setting the level and composition of remuneration for directors and senior executives and ensuring that such remuneration is appropriate and not excessive: https://anataralifesciences.com/investors/corporate-governance/ With the retirement of an independent non-executive director on 2 October 2023, the Remuneration and Nominations Committee currently has three members including two executive directors. The committee is not currently chaired by an independent non-executive director until an additional independent non-executive director is appointed.	☐ set out in our Corporate Governance Statement OR ☐ we are an externally managed entity and this recommendation is therefore not applicable
8.2	A listed entity should separately disclose its policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives.	☒ and we have disclosed separately our remuneration policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives at: https://anataralifesciences.com/investors/annual-reports/	☐ set out in our Corporate Governance Statement OR ☐ we are an externally managed entity and this recommendation is therefore not applicable

Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation		Where a box below is ticked, ⁴ we have followed the recommendation <u>in full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: ⁵
8.3	A listed entity which has an equity-based remuneration scheme should: (a) have a policy on whether participants are permitted to enter into transactions (whether through the use of derivatives or otherwise) which limit the economic risk of participating in the scheme; and (b) disclose that policy or a summary of it.	☒ and we have disclosed our policy on this issue or a summary of it at: https://anataralifesciences.com/investors/annual-reports/	☐ set out in our Corporate Governance Statement <u>OR</u> ☐ we do not have an equity-based remuneration scheme and this recommendation is therefore not applicable <u>OR</u> ☐ we are an externally managed entity and this recommendation is therefore not applicable
ADDITIONAL RECOMMENDATIONS THAT APPLY ONLY IN CERTAIN CASES			
9.1	A listed entity with a director who does not speak the language in which board or security holder meetings are held or key corporate documents are written should disclose the processes it has in place to ensure the director understands and can contribute to the discussions at those meetings and understands and can discharge their obligations in relation to those documents.	☐ and we have disclosed information about the processes in place at: [insert location]	☐ set out in our Corporate Governance Statement <u>OR</u> ☒ we do not have a director in this position and this recommendation is therefore not applicable <u>OR</u> ☐ we are an externally managed entity and this recommendation is therefore not applicable
9.2	A listed entity established outside Australia should ensure that meetings of security holders are held at a reasonable place and time.	☐	☐ set out in our Corporate Governance Statement <u>OR</u> ☒ we are established in Australia and this recommendation is therefore not applicable <u>OR</u> ☐ we are an externally managed entity and this recommendation is therefore not applicable
9.3	A listed entity established outside Australia, and an externally managed listed entity that has an AGM, should ensure that its external auditor attends its AGM and is available to answer questions from security holders relevant to the audit.	☐	☐ set out in our Corporate Governance Statement <u>OR</u> ☒ we are established in Australia and not an externally managed listed entity and this recommendation is therefore not applicable ☐ we are an externally managed entity that does not hold an AGM and this recommendation is therefore not applicable

Key to Disclosures Corporate Governance Council Principles and Recommendations

Corporate Governance Council recommendation		Where a box below is ticked, ⁴ we have followed the recommendation <u>in full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: ⁵
ADDITIONAL DISCLOSURES APPLICABLE TO EXTERNALLY MANAGED LISTED ENTITIES			
-	<i>Alternative to Recommendation 1.1 for externally managed listed entities:</i> The responsible entity of an externally managed listed entity should disclose: (a) the arrangements between the responsible entity and the listed entity for managing the affairs of the listed entity; and (b) the role and responsibility of the board of the responsible entity for overseeing those arrangements.	☐ and we have disclosed the information referred to in paragraphs (a) and (b) at: <i>[insert location]</i>	☐ set out in our Corporate Governance Statement
-	<i>Alternative to Recommendations 8.1, 8.2 and 8.3 for externally managed listed entities:</i> An externally managed listed entity should clearly disclose the terms governing the remuneration of the manager.	☐ and we have disclosed the terms governing our remuneration as manager of the entity at: <i>[insert location]</i>	☐ set out in our Corporate Governance Statement

Corporate Governance Statement

Principles and Recommendations	Compliance	
Principle 1 Lay solid foundations for management and oversight		
1.1 <i>A listed entity should disclose: (a) the respective roles and responsibilities of its board and management; and (b) those matters expressly reserved to the board and those delegated to management.</i>	The Board is responsible for overall corporate governance of the Company. The role of the Board and delegation to management have been formalised in the Charter which outlines the main corporate governance practices in place for the Company and to which the Board and each Director are committed. The conduct of the Board is also governed by the Constitution, and where there is inconsistency with that document, the Constitution prevails to the extent of the inconsistency with that document, the Constitution prevails to the extent of the inconsistency. The Charter is reviewed and amended from time to time as appropriate taking into consideration practical experience gained in operating as a listed company.	Complies
1.2 <i>A listed entity should: (a) undertake appropriate checks before appointing a person or putting forward to security holders a candidate for election, as a director; and (b) provide security holders with all material information in its possession relevant to a decision on whether or not to elect or re-elect a director.</i>	The Company has completed police checks, insolvency and banned director searches in relation to the existing directors. The Company will conduct appropriate checks before future directors are appointed.	Complies
1.3 <i>A listed entity should have a written agreement with each director and senior executive setting out the terms of their appointment.</i>	The Company has entered into written agreements with each director and senior executive.	Complies
1.4 <i>The company secretary of a listed entity should be accountable directly to the board, through the chair, on all matters to do with the proper functioning of the board.</i>	This is consistent with the Charter and corporate structure of the Company. The Company Secretary has a direct relationship with the Board in relation to these matters and operates independently of the executive.	Complies

Corporate Governance Statement

1.5	<i>Establish a diversity policy and disclose the policy or a summary of that policy. The policy should include requirements for the board to establish measurable objectives for achieving gender diversity and for the board to assess annually both the objectives and progress in achieving them, for reporting against in each reporting period.</i>	The diversity policy for the Company has been implemented and the Company reported on measurable objectives in this policy. This Policy is disclosed on the Company's website under Investor Relations / Corporate Governance.	Complies
1.6	<i>A listed entity should (a) have and disclose a process for periodically evaluating the performance of the Board, its committees and individual directors; and (b) disclose, in relation to each reporting period, whether a performance evaluation was undertaken in the reporting period in accordance with that process.</i>	The Board Charter provides for regular performance reviews to be conducted. A recent performance evaluation was undertaken in accordance with that process.	Complies
1.7	<i>A listed entity should (a) have and disclose a process for periodically evaluating the performance of its senior executives; and (b) disclose, in relation to each reporting period, whether a performance evaluation was undertaken in the reporting period in accordance with that process.</i>	The Board's broad function is to define the Company's purpose, approve the Company's statement of values and code of conduct, chart strategy and set financial targets for the Company, monitor the implementation and execution of strategy and performance against financial targets, appoint and oversee the performance of executive management, and generally to take an effective leadership role in relation to the Company. The Chairman, with assistance from the Remuneration and Nominations Committee, annually assesses the performance of Directors and senior executives, and the Chairman's performance is assessed by the other Directors. Performance evaluations have been undertaken in accordance with that process.	Complies

Corporate Governance Statement

Principle 2 Structure the board to add value

2.1 The board of a listed entity should:

(a) have a nomination committee which:

(1) has at least three members, a majority of whom are independent directors; and

(2) is chaired by an independent director, and disclose:

(3) the charter of the committee;

(4) the members of the committee; and

(5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or

(b) if it does not have a nomination committee, disclose that fact and the processes it employs to address board succession issues and to ensure that the board has the appropriate balance of skills, knowledge, experience, independence and diversity to enable it to discharge its duties and responsibilities effectively.

A Remuneration and Nominations Committee has been established with its own Charter. The committee members consists of David Brookes, Nicholas Haslam and John Michailidis as committee chair (joined on 2 October 2023). The Remuneration and Nominations Committee does not comply with recommendation 2.4, which recommends that the Committee have at least three members, the majority of whom must be independent as Mr Michailidis and Dr David Brookes are both executive directors. This Charter is disclosed on the Company's website under Investor Relations / Corporate Governance. An additional independent non-executive director will be appointed to the committee when appointed to the board and likely to be appointed as the chair of a 3 member committee.

Complies in part

Corporate Governance Statement

2.2 A listed entity should have and disclose a board skills matrix setting out the mix of skills and diversity that the board currently has or is looking to achieve in its membership.

The Board considers that its membership should comprise directors with an appropriate mix of skills, experience and personal attributes that allow the directors individually and the Board collectively to discharge their responsibilities and duties under the law effectively and efficiently. Directors should understand the Anantara business and the environment in which Anantara operates so as to be able to question and agree with management on the objectives, goals and strategic direction which will maximise shareholder value, and then assess the performance of management in meeting those objectives and goals.

The current directors collectively bring to the Board a broad range of experience, expertise, skills, diversity and contacts relevant to Anantara and its business development and goals. The biographies of all directors can be found in the Annual Report for the year ended 30 June 2024.

The Board skills matrix set out below describes the combined skills, experience and expertise presently represented on the Board. The Board strives to achieve diversity in its composition, and gender diversity continues to be a focus and goal.

Skills, experience and expertise:

- Academia
-
- Consumer Products
- Global Business & Finance
- Human Health
- Life Sciences
- Manufacturing & Supply
- Marketing & Sales
- Mergers & Acquisitions
- Other Public Company Board Member
- Public Company CEO, CFO, General Counsel, Compliance or Corporate Governance
- Regulated Industries
- Research & Development

Complies

Corporate Governance Statement

2.3 <i>A listed entity should disclose: (a) the names of the directors considered by the board to be independent directors; (b) if a director has an interest, position, association or relationship of the type described in Box 2.3 but the board is of the opinion that it does not compromise the independence of the director, the nature of the interest, position, association or relationship in question and an explanation of why the board is of that opinion; and (c) the length of service of each director.</i>	The Board considers each of the following directors to be independent: Nicholas Haslam (appointed 7 December 2022) David Brookes (appointed 23 January 2019) Note David Brookes is currently an executive chair. A Chief Operating Officer was appointed concurrently (a new position). This structure will remain until a full-time Chief Executive Officer is appointed. At that time it is intended that David Brookes will transition to a non-executive director role. Mr John Michailidis (appointed 2 October 2023) Note Mr Michailidis is currently the Chief Operating Officer. It is planned that an independent non-executive director will be appointed at the appropriate time and that with future executive recruitment, Mr Michailidis roles will be reconsidered within the new structure with the intention to transition to a non-executive director role.	Complies
2.4 <i>A majority of the board of a listed entity should be independent directors.</i>	Refer 2.3; current governance structure is pragmatic and recognized as for a transitional period as Company needs and path further determined	Complies in part
2.5 <i>The Chair of the board of a listed entity should be an independent director and, in particular, should not be the same person as the CEO of the entity.</i>	Refer 2.3 & 2.4 The Company currently has a three-member Board, of whom one is an independent non-executive director. Refer 2.3 & 2.4. Up to 2 October 2023 the Company had two of three independent non-executive directors.	Complies in part
2.6 <i>A listed entity should have a program for inducting new directors and provide appropriate professional development opportunities for directors to develop and maintain the skills and knowledge needed to perform their role as directors effectively.</i>	The Chairman, Dr. David Brookes, is currently an Executive Chairman and it is anticipated a CEO will be appointed in this financial year. This is consistent with the Board Charter and processes implemented by Anantara.	Complies in part

Corporate Governance Statement

Principle 3 Act ethically and responsibly

3.1	<i>A listed entity should articulate and disclose its values.</i>	The Company has adopted Core Values to ensure that all employees share a common set of core values which underpin the way they work in pursuit of shared objectives. These Core Values are disclosed on the Company's website under Investor Relations/Corporate Governance.	Complies
3.2	<i>A listed entity should: (a) have and disclose a code of conduct for its directors, senior executives and employees; and (b) ensure that the board or a committee of the board is informed of any material breaches of that code.</i>	The Company has adopted a Code of Conduct ensuring that all employees, collaborators and contractors observe the highest standards of ethical behaviour and conduct and follow the principles of corporate social responsibility. All material breaches of this Code of Conduct must be reported to the board or a board committee. This Code of Conduct is disclosed on the Company's website under Investor Relations / Corporate Governance.	Complies
3.3	<i>A listed entity should: (a) have and disclose a whistleblower policy; and (b) ensure that the board or a committee of the board is informed of any material breaches of that policy.</i>	The Company has adopted a Whistleblower Policy. All material incidents must be reported to the board. This Policy is disclosed on the Company's website under Investor Relations/Corporate Governance.	Complies
3.4	<i>A listed entity should: (a) have and disclose an anti-bribery and corruption policy; and (b) ensure that the board or a committee of the board is informed of any material breaches of that policy.</i>	The Company has adopted an Anti-Bribery and Corruption Policy. All material breaches must be reported to the board. This Policy is disclosed on the Company's website under Investor Relations/Corporate Governance.	Complies

Corporate Governance Statement

Principle 4 Safeguard integrity in corporate reporting

4.1 <i>The board of a listed entity should: (a) have an audit committee which: (1) has at least three members, all of whom are non-executive directors and a majority of whom are independent directors; and (2) is chaired by an independent director, who is not the chair of the board, and disclose: (3) the charter of the committee; (4) the relevant qualifications and</i>	The Company has established an Audit and Risk Management Committee to assist and report to the Board. The Audit and Risk Management Committee consists of Nicholas Haslam (committee chair), and two executive directors. The Committee is chaired by an independent Director who is not the Board Chairman. Mr John Michailidis joined the Board and the Audit & Risk Committee as of 2 October 2023 as an executive director and therefore not viewed as independent. In addition Dr David Brookes was an independent member until he assumed the executive chair role in June 2022. He remains a member of the Audit & Risk Committee. Hence, the Committee does not currently comply with the recommendations around independence and non-executive directors which will be addressed with any future appointment of an independent director and/or change in the current management structure.	Complies in part
--	--	------------------

Corporate Governance Statement

experience of the members of the committee; and (5) in relation to each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have an audit committee, disclose that fact and the processes it employs that independently verify and safeguard the integrity of its corporate reporting, including the processes for the appointment and removal of the external auditor and the rotation of the audit engagement partner.

The Audit and Risk Management Committee Charter is disclosed on the Company's website under Investor Relations / Corporate Governance.

4.2 *The board of a listed entity should, before it approves the entity's financial statements for a financial period, receive from its CEO and CFO, a declaration that, in their opinion, the financial records of the entity have been properly maintained and that the financial statements comply with the appropriate accounting standards and give a true and fair view of the financial position and performance of the entity and that the opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.*

This is consistent with the approach to be adopted by the Audit and Risk Management Committee and Board.

Complies

4.3 *A listed entity should disclose its Process to verify the integrity of Any periodic corporate report it Releases to the market that is not audited or reviewed by an external auditor.*

Anatara releases an annual directors' report, annual and half yearly financial statements and, quarterly cash flow reports. The annual and half yearly financial statements are reviewed by an external auditor. The quarterly cash flow report is prepared by an external accounting firm. The quarterly cash flow report and directors' report are reviewed by the directors.

Complies

Corporate Governance Statement

Principle 5 Make timely and balanced disclosure

5.1	A listed entity should have and disclose a written policy for complying with its continuous disclosure obligations under Listing Rule 3.1.	Anatara has a written continuous disclosure policy which is designed to ensure that all material matters are appropriately disclosed in a balanced and timely manner and in accordance with the requirements of the ASX Listing Rules. This Policy is disclosed on the Company's website under Investor Relations/Corporate Governance.	Complies
5.2	A listed entity should ensure that its board receives copies of all material market announcements promptly after they are made.	Anatara's independent company secretary distributes all ASX announcements promptly after they are made.	Complies
5.3	A listed entity that gives a new and substantive investor or analyst presentation should release a copy of the presentation materials on the ASX Market Announcements Platform ahead of the presentation.	Before Anatara delivers any new and substantive investor/analyst presentation, a copy of the presentation is released to the ASX. Copies of all investor presentations are also disclosed on the Company's website under Investor Relations/Presentations.	Complies

Corporate Governance Statement

Principle 6 Respect the rights of security holders

6.1	<i>A listed entity should provide information about itself and its governance to investors via its website.</i>	The Board Charter and other applicable policies are available on the Company's website.	Complies
6.2	<i>A listed entity should design and implement an investor relations program to facilitate effective two-way communication with investors</i>	The Company aims to ensure that all Shareholders are well informed of all major developments affecting the Company. The Company has a Securityholder Communications Policy to promote effective communication with securityholders and encourage effective participation at general meetings of the Company. This policy is disclosed on the Company's website under Investor Centre/Corporate Governance.	Complies
6.3	<i>A listed entity should disclose how it facilitates and encourages participation at meetings of security holders</i>	The Company has a Securityholder Communications Policy to promote effective communication with securityholders and encourage effective participation at general meetings of the Company. This policy is disclosed on the Company's website under Investor Centre/Corporate Governance.	Complies
6.4	<i>A listed entity should ensure all substantive resolutions at a meeting of security holders are decided by a poll rather than a show of hands.</i>	There has been voting by POLL on ALL resolutions put to shareholders since the 2019 AGM.	Complies
6.5	<i>A listed entity should give security holders the option to receive communications from, and send communications to, the entity and its security registry electronically.</i>	The Company has instructed its share registry to facilitate this option for investors, as well as future shareholders at appropriate times.	Complies

Corporate Governance Statement

Principle 7 Recognise and manage risk

7.1 <i>The board of a listed entity should: (a) have a committee or committees to oversee risk, each of which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have a risk committee or committees that satisfy (a) above, disclose that fact and the processes it employs for overseeing the entity's risk management framework.</i>	The Company has a combined Audit and Risk Management Committee to oversee risk. See above for independent status of the committee members. The functions and operations of the Committee are established under the Charter. This Charter is disclosed on the Company's website under Investor Relations/Corporate Governance. The number of times the committee met throughout each period and individual attendances is disclosed in the Company's Annual Report.	Complies in part
7.2 <i>The board or a committee of the board should: (a) review the entity's risk management framework at least annually to satisfy itself that it continues to be sound; and (b) disclose, in relation to each reporting period, whether such a review has taken place</i>	The Charter establishes the role of the committee. The committee established the risk management framework and has reviewed it during the reporting period to satisfy itself that it continues to be sound.	Complies
7.3 <i>A listed entity should disclose: (a) if it has an internal audit function, how the function is structured and what role it performs; or (b) if it does not Have an internal audit function, that fact and the processes it employs for evaluating and continually improving the effectiveness of Its risk management and internal control processes.</i>	Due to the Company's limited number of employees and relative nature and scale of its operations, the costs of an independent audit function would be disproportionate. The Company has an external auditor, and the Audit and Risk Management Committee will monitor and evaluate material or systemic issues. The Board believes it and the Audit and Risk Management Committee have adequate oversight of the existing operations.	Complies
7.4 <i>A listed entity should disclose whether it has any material exposure to economic, environmental and social sustainability risks and if it does, how it manages or intends to manage those risks.</i>	The Board does not believe the Company has any such material risks. The Company operates in accordance with the regulatory and ethical standards prescribed by the TGA and APVMA in Australia and other relevant regulators overseas.	Complies

Corporate Governance Statement

Principle 8 Remunerate fairly and responsibly

8.1 <i>The board of a listed entity should: (a) have a remuneration committee which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have a remuneration committee, disclose that fact and the processes it employs for setting the level and composition of remuneration for directors and senior executives and ensuring that such remuneration is appropriate and not excessive.</i>	The Board has established a combined Remuneration and Nominations Committee to assist the Board to discharge its responsibilities in relation to remuneration and issues relevant to remuneration policies and practices, including those for senior management and non-executive Directors. The Remuneration and Nominations Committee consists of Nicholas Haslam (from 2 October 2023), David Brookes and Mr John Michailidis as Committee chair. Until 2 October 2023 it has consisted of a majority of independent directors, is now chaired by an executive director who is not the Chairman and has at least three members. Matters relating to the Committee Chair's management role including assessment are conducted by the other members of the Committee. It is intended to appoint an additional independent non-executive director as soon as is practicable. The composition and role of the Remuneration and Nominations Committee is set out in the Remuneration and Nominations Committee charter. This Charter is disclosed on the Company's website under Investor Relations/Corporate Governance.	Complies in part
8.2 <i>A listed entity should separately disclose its policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives.</i>	The Company has adopted remuneration policies which comply with the Guidelines including separately disclosing the remuneration of nonexecutive directors, and the remuneration of executive directors and other senior executives. No senior executive is involved directly in deciding their own remuneration. The Company's remuneration policies are disclosed in each Annual Report.	Complies
8.3 <i>A listed entity which has an equity-based remuneration scheme should:</i> <i>(a) have a policy on whether participants are permitted to enter into transactions (whether through the use of derivatives or otherwise) which limit the economic risk of participating in the scheme; and</i> <i>(b) disclose that policy or a summary of it.</i>	In accordance with the Company's share trading policy, participants in any equity-based incentive scheme are prohibited from entering into any transaction that would have the effect of hedging or otherwise transferring the risk of any fluctuation in the value of any unvested entitlement in the Company's securities to any other person. The details of the scheme have been through the process of regular review and shareholder approval at AGM.	Complies